Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.

Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.

Item
http://www.wikidata.org/entity/Q34079832
Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a reviewOne-Day Use of Preoperative Topical Nonsteroidal Anti-Inflammatory Drug Prevents Intraoperative Prostaglandin Level Elevation During Femtosecond Laser-Assisted Cataract Surgery.Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single siteComparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy.Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.Topical nonsteroidal anti-inflammatory drugs for macular edema.Prophylactic postoperative ketorolac improves outcomes in diabetic patients assigned for cataract surgery.Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration.Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.Comparison of ketorolac 0.45% versus diclofenac 0.1% for macular thickness and volume after uncomplicated cataract surgery.
P2860

Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.

Item
http://www.wikidata.org/entity/Q34079832
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@ast
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@en
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@nl
type
label
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@ast
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@en
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@nl
prefLabel
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@ast
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@en
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P356
P1433
P1476
Prostaglandin E2 inhibition of ...... ndergoing phacoemulsification.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698